Work

The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs: The Case of Bevacizumab for Breast Cancer

Year: 2020

Type: article

Abstract: Spending on physician-administered drugs is high and uses not approved by the U.S. Food and Drug Administration (FDA) are frequent. While these drugs may be targets of future policy efforts to rationalize use, little is known regarding how physicians respond to emerging safety and effectiveness evidence.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/xsr7-g582

Authors: Conti, Rena M., Berndt, Ernst R., Herbert, Ann C., Huskamp, Haiden A., Dusetzina, Stacie B., Keating, Nancy L.

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4298315664

FWCI:

Cites:

Cited by:

Related to: 10